Changeflow GovPing Pharma & Healthcare Impact of PDT and Topical Corticosteroids on Ta...
Routine Notice Added Final

Impact of PDT and Topical Corticosteroids on Taste Perception in Patients With OLP

Favicon for changeflow.com ClinicalTrials.gov Studies
Published
Detected
Email

Summary

NIH ClinicalTrials.gov registered a new comparative effectiveness study (NCT07536737) evaluating photodynamic therapy versus topical corticosteroids for treating oral lichen planus and their effects on taste perception. The randomized controlled trial will enroll patients receiving either 5-Amino Levulinic Acid-based PDT or Clobetasol Propionate 0.05% Cream, assessing taste recognition and lesion outcomes. Study findings may inform clinical treatment selection for OLP patients experiencing taste disturbances.

Published by NIH on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

NIH registered a new clinical trial on ClinicalTrials.gov (NCT07536737) comparing photodynamic therapy (PDT) using 5-Amino Levulinic Acid with topical Clobetasol Propionate 0.05% Cream for treating oral lichen planus. The study will evaluate taste perception changes and symptom reduction across two treatment arms. Participants undergo taste strip testing and lesion assessments before and after therapy.

Healthcare providers and clinical investigators conducting oral medicine or dermatology research may find this study relevant for understanding comparative OLP treatment outcomes. The study represents standard clinical research registration activity and does not impose compliance obligations on regulated entities beyond standard clinical trial requirements.

Archived snapshot

Apr 18, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← ClinicalTrials.gov Studies

Impact of PDT and Topical Corticosteroids on Taste Perception in Patients With OLP

N/A NCT07536737 Kind: NA Apr 17, 2026

Abstract

Oral lichen planus (OLP) is a chronic inflammatory disease that affects the lining of the mouth and may cause pain, burning sensations, and discomfort. Some patients also report changes in their ability to taste different flavors.

The aim of this study is to compare two commonly used treatments for OLP: photodynamic therapy (PDT) and topical corticosteroids. PDT is a light-based treatment that uses a special gel applied to the affected areas, followed by illumination with a medical light device. Topical corticosteroids are anti-inflammatory medications applied directly to the lesions.

Participants in this study are randomly assigned to receive one of these two treatments. Before starting therapy and immediately after its completion, patients undergo a simple taste test using special strips that assess the ability to recognize sweet, sour, salty, and bitter tastes. In addition, the size of oral lesions and the intensity of symptoms such as pain or burning are evaluated.

The results of this study may help to better understand how different treatments for oral lichen planus affect taste perception and overall patient well-being, and may support the selection of the most appropriate therapy in clinical practice.

Conditions: Oral Lichen Planus

Interventions: 5-Amino Levulinic Acid, Clobetasol Propionate 0.05% Cream

View original document →

Get daily alerts for ClinicalTrials.gov Studies

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Published
April 17th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
NCT07536737

Who this affects

Applies to
Healthcare providers Clinical investigators Patients
Industry sector
6211 Healthcare Providers
Activity scope
Clinical research Drug clinical trials Medical treatment evaluation
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Clinical Operations
Topics
Pharmaceuticals Medical Devices

Get alerts for this source

We'll email you when ClinicalTrials.gov Studies publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!